検索
Valneva SE
VALNウォッチリストに追加
6.220USD
-0.130-2.05%
終値 09-24 16:00（ET）
589.80M時価総額
損失額直近12ヶ月PER
Valneva SEについて 企業名
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE プロフィール
企業コードVALN
会社名Valneva SE
上場日Jun 28, 2007
最高経営責任者「CEO」Lingelbach (Thomas)
従業員数- -
証券種類Depository Receipt
決算期末Jun 28
本社所在地6, Rue Alain Bombard
都市SAINT-HERBLAIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国France
郵便番号44800
電話番号33228073710
ウェブサイトhttps://valneva.com/
企業コードVALN
上場日Jun 28, 2007
最高経営責任者「CEO」Lingelbach (Thomas)
Valneva SEの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Ms. Petra Pesendorfer
Ms. Petra Pesendorfer
Chief People Officer
Chief People Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
よくある質問
Valneva SEの上位5名の株主は誰ですか？
Valneva SEの上位5名の株主は以下のとおりです。Mr. James R. Sulat
Valneva SE（VALN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Valneva SEの株式を保有している機関は36社あり、保有株式の総市場価値は約5.21Mで、全体の5.50%を占めています。2025Q4と比較して、機関の持ち株は-309162.00増加しています。
Valneva SEの最大の収益源は何ですか？
2026Q1において、IXIARO部門がValneva SEにとって最大の収益を生み出しており、その金額は98.42Mで、全収益の56.35%を占めています。